An important change for people with diabetes. As of July 1, this medicine is now free

• Since July 1, insulin glargine analogues, including Toujeo, have also been reimbursed for children aged 6 and over with type 1 diabetes.
• The substance was added to the free D1 list of drugs for patients up to 18 years of age, based on the assessment of AOTMiT and the decision of the Minister of Health
• Toujeo, with a concentration of 300 IU/ml, is intended for patients with a higher need for basal insulin and works evenly throughout the day
• Reimbursement of insulin analogues in Poland began in 2013 and was gradually extended to other patient groups and preparations.

Since July 1, in accordance with the new list of reimbursed drugs, insulin glargine analogues can also be used in children from the age of 6. By decision of the Minister of Health - based on the assessment of the Agency for Health Technology Assessment and Tariff System - the substance has also been included in the free list D1 (drugs 18 minus), like other insulins from group 14.3 - pancreatic hormones, long-acting insulin analogues.

This is an important change from the perspective of families of children with type 1 diabetes, because until now the drug was only available for adults .

Toujeo – solution for injection (300 IU/ml, 10 SoloStar pens of 1.5 ml each) – thanks to its higher concentration it can be used in patients with a higher need for basal insulin.

Insulin analogues, introduced to the market in the 1990s, are modified human insulin molecules obtained by recombinant DNA technology. Long-acting analogues release insulin slowly and evenly , which allows for stabilization of blood sugar levels around the clock and allows for once-daily dosing.

In Poland, reimbursement of analogues began in 2013 – first for adults with type 2 diabetes and children aged 2–6 with type 1 diabetes (Lantus). Over time, the list of reimbursed drugs and the criteria for their use were gradually expanded.

Toujeo insulin has been reimbursed since 2017 for adult patients with type 1 and 2 diabetes. From July 1, the drug will also be reimbursed for children with type 1 diabetes who are 6 years of age or older.

Copyrighted material - reprint rules are specified in the regulations .